Drugs / HEMOPEXIN (HUMAN)
HEMOPEXIN (HUMAN)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04285827 | May 2021 → Jul 2023 | sickle cell disease | CSL Behring | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06699849 | Aug 2025 → Oct 2027 expected | sickle cell disease | CSL Behring | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-11-02 | CSL Behring | Regulatory Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease csl.com ↗
CSL Behring announced today that its investigational, plasma-derived hemopexin therapy (CSL889) received orphan drug designation from both the European Commission and the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for the treatment of sickle cell disease (SCD). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-11-02 | CSL Behring | Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease csl.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEMOPEXIN (HUMAN) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315017 ↗ |
| Known as | Beta-1b-glycoprotein | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315017 ↗ |
| Known as | CSL889 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06699849 ↗ |
| Known as | Haemopexin | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315017 ↗ |
| Known as | Hemopexin (plasma derived) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315017 ↗ |
| Modality | Protein / enzyme biologic | “CSL889 (human hemopexin)” NCT06699849 ↗ |
| Route | Intravenous | “Administered as an IV infusion” NCT04285827 ↗ |